5

Fracture liaison programs

Piet Geusens a, b, *, Sandrine P.G. Bours a, Caroline E. Wyers c, d, Joop P. van den Bergh b, c, d

a Department of Internal Medicine, Subdivision Rheumatology, CAPHRI Care and Public Health Research Institute, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, the Netherlands
b Biomedical Research Centre, Hasselt University, Agoralaan, Gebouw D, 3590 Diepenbeek, Belgium
c Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, the Netherlands
d Department of Internal Medicine, VieCuri Medical Centre, Tegelseweg 210, 5912 BL Venlo, the Netherlands

Keywords:
Fracture liaison service
Orthogeriatric care
Implementation
Fracture risk evaluation
Secondary osteoporosis
Secondary fracture prevention
Cost/effectiveness

ABSTRACT

In view of the high imminent risk of having subsequent fractures after a fracture, early evaluation and treatment decisions to prevent subsequent fractures are advocated. After a hip fracture, the fracture liaison service (FLS) and orthogeriatric care are considered the most appropriate organisational approaches for secondary fracture prevention following a recent fracture. Their introduction and implementation have been shown to increase evaluation and treatment of patients at high risk for subsequent fracture. Of real-world cohort studies, most, but not all studies, indicate a lower incidence of fracture and longer survival after treatment with nitrogen-containing bisphosphonates.

© 2019 Elsevier Ltd. All rights reserved.

At the age of 50 years, 50% of women and 25% of men will sustain a fracture during the remaining lifetime [1]. Subsequent fractures contribute substantially to this overall fracture burden. Of all low-trauma fractures after the age of 40 years, 40% of fractures in women and 24% in men are subsequent fractures [2]. Nearly all fractures are associated with an increased risk for future fracture, regardless of age, baseline bone mineral density (BMD) and fracture location [3–5]. Furthermore, most
subsequent fractures occur within the first years after a fracture, which is refereed as the ‘imminent fracture risk’, i.e. the risk of having subsequent fracture is higher in short term than in long term after a fracture [6].

To prevent subsequent fractures, patients with a recent fracture are, therefore, in need of adequate evaluation and treatment decisions shortly after the initial fracture. However, there is still a large gap in the number of patients with a recent fracture who are actually evaluated and treated [7–9]. In this context, the American Society of Bone and Mineral Research (ASBMR), the International Osteoporosis Foundation (IOF) and the European League against Rheumatism (EULAR) together with the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) have formulated recommendations for secondary fracture prevention [10–12].

The FLS is considered the most effective organisational structure to increase evaluation and treatment after any fracture [13] and orthogeriatric care in frail elderly after hip fracture (meta-analysis and randomised control trial (RCT)) [13].

The four pillars of an FLS

Building up an FLS requires four pillars (Fig. 1). The first pillar consists of a bone leader, a coordinator, a multidisciplinary team and a business plan to run an FLS [10–12,14,15]. The bone leader is a specialist in metabolic bone diseases who takes care of the organisation of a multidisciplinary team in consultation with the orthopaedic surgeons. The coordinator, often a well-educated nurse, is responsible for organising the diagnostic investigations and to help starting interventions and providing adequate medical information to patients and general practitioners (GPs) [10–12,16,17].

The second pillar consists of the identification of all patients with a recent fracture and the selection of patients for invitation to the FLS [10–12]. Selected patients have to be educated, contacted and invited [13,18]. This can be performed at the emergency department, at the plaster consultation, in the hospital when patients are hospitalised, at the orthogeriatric care unit and at post-treatment stage after fracture healing, by regular fracture database consultation, information letter, telephone call and
e-mail. Such coordinator-supported approach has been shown to significantly increase evaluation and treatment initiation [13,19].

A third pillar consists of orthogeriatric care, which focuses on patients with a recent hip fracture. Orthogeriatric services are designed to provide specialist geriatric care to the frail older trauma patient and are integral to multidisciplinary management following admission preoperatively, peri-operatively and post-operatively. The components include rapid optimisation of fitness for surgery, early identification of rehabilitation goals to facilitate return to pre-fracture residence and long-term well-being, as appropriate, and integrating with related services within secondary care and the community, including secondary fracture prevention. The development of orthogeriatrician-led FLS models focuses mainly on patients with hip fractures but could also be a model for admitted frail elderly with a recent major fracture, whereas ambulatory patients with non-vertebral fractures (NVFs) and vertebral fractures (VFs) are preferably managed in an outpatient FLS setting [20–22].

The fourth pillar is communication with the GP and organisation of adequate follow up.

Reasons for evaluation and treatment gap after a fracture

Currently, there is a substantial treatment gap for osteoporosis in general, which is highly variable throughout Europe, i.e. between 25% and 95% [8,23,24]. Various reasons have been documented for this gap. Most patients perceive their risk for future fractures as low [25], also patients with comorbidities such as neurologic, rheumatologic, respiratory and gastro-intestinal comorbidities [26]. Even patients with postmenopausal osteoporosis perceive fractures as random events, related to hazards in the environment such as accidental falls or unsafe behaviour [27]. Patients referred for bone densitometry accept considerably higher fracture risk than doctors to justify drug treatment [28] and have difficulties understanding the concept of 10 year risk [27,29]. On the other hand, post-fracture osteoporosis medication use was higher in women than in men, in patients with previously diagnosed osteoporosis and in those who had a BMD assessment before the fracture [30].

Patients, the lay press, the medical literature and doctors, especially those treating tooth problems, have - sometimes excessive - concerns about side effects such as atypical femoral fractures (AFFs) and osteonecrosis of the jaw [31–33]. Other reasons for the evaluation and treatment gap are older age, residing in long-term care and lack of education about benefits and risks of treatment in patients, the lay press and even GPs [8,34,35]. In addition, there may be factors that attribute to the evaluation and treatment gap related to doctors and to local or national health organisations. Examples are the lack of a local bone leader and fracture nurse, lack of communication between specialists and between specialists and GPs, and insufficient organisational and financial support from local or national health organisations [10–13,15,18,36–39].

Case finding: how to organise transfer from fracture treatment to secondary fracture prevention?

Implementation of an FLS requires arranging systematic identification of all patients who enter the ED because of a fracture. Of the identified patients, those with following criteria need to be selected: >50 years old, excluding finger, toe, skull and pathologic and major traffic accident fractures. These selected patients then need to be informed about their potential subsequent imminent and long-term fracture risk and invited to attend the FLS for counselling, evaluation and treatment according to personalised precision medicine.

Many attempts have been undertaken to organise the transfer of patients with a recent fracture after acute fracture care towards secondary fracture prevention [13,18]. Examples are education of patients with a recent fracture and alerting the GP by a discharge letter. However, such approach is less effective than an FLS [13].

Which patients should be selected for evaluation at the FLS?

Apart from orthopaedic descriptions of fractures (comminute, transverse, oblique etc.), there are many definitions in the literature for characterising the complex nature of a fracture (Fig. 2) [40–42].
These descriptions refer to different diagnostic skeletal and extra-skeletal characteristics associated with a fracture.

These variable fracture descriptions sometimes result in Babylonian confusion between clinicians regarding which patient with the above-described definitions to evaluate and treat in the context of the FLS. There is general consensus to invite following patients at the FLS:

- Women and men, 50 years or older, with a recent fracture
- All fracture locations (except fingers, toes, face and skull), and more specifically:
- Low trauma fractures, defined as fractures sustained due to fall(s) from standing height or lesser height and by extension of other low traumas (see above)
- Patients who sustain a moderate-to high-trauma fracture are also at increased risk of having subsequent fracture and could warrant inclusion (except after a major traffic accident) [3,15,43].

**Which patients attend the FLS?**

Although VFs are the most common incident fractures after the age of 50 years in women and men [1], most patients who are visiting the Emergency Department present with an NVF [15]. Most VFs are not recognised because they occur sub-clinically, without typical clinical signs and symptoms of an acute fracture [44,45], and because imaging of the spine is not performed in many patients with acute back pain [46]. In addition, VFs may not even be diagnosed when spine images are available [47], and, when diagnosed, they are often not treated or treated ambulatory [48].

In a recent overview, it was reported that FLSs varied in terms of patient identification, selection and FLS attendance [49]. Patient identification and selection differed markedly among FLSs, in terms of proportions of inpatients and outpatients, age, inclusion of women and/or men and fracture selection (any fracture or only patients with a NVF). Exclusion criteria for FLS invitation also differed, such as high-energy trauma fractures, pathological fractures and cognitive impairment. In addition, 20–89% of
the patients selected for evaluation at the FLS actually attended the FLS. As a result, literature regarding FLSs contains a high variability in FLS patient characteristics, such as mean age (64–80 years), proportion of men (13–30%) and fracture locations (2–51% hip, <1–41% vertebral and 49–95% non-hip, NVFs) [49].

In a national patient-level audit of the quality of FLSs in the UK, 18,356 patients were enrolled from 38 FLSs. It was concluded that national coverage of secondary fracture prevention using FLSs is still low with variability in quality between existing FLSs [50]. Although completeness of submitted data varied, there was also marked variability in the proportion of patients meeting recognised standards of care in the identification of fragility fracture patient, timely initial contact and subsequent risk assessment, and treatment initiation and monitoring [50].

In the Netherlands, where most of the hospitals run an FLS, in a study of 24,468 patients, those attending the FLS were evaluated, treated and followed in high compliancy with the local guidelines and with IOF standards [51]. However, the major shortcoming in FLS care was that patients invited to attend the FLSs showed a low attendance rate of approximately 50%. The Kaiser Permanente Healthy Bones Program is yet another programme developed for fracture prevention [52]. Data gathered by the Capture the Fracture initiative of the IOF are available. It shows that currently >300 FLSs received a gold status worldwide [53].

**Fracture risk evaluation**

The aim of fracture risk evaluation after a recent fracture is, first, to identify the presence and extent of risk factors of having subsequent fracture risk and, second, initiate appropriate treatment according to the patient’s risk.

Meanwhile, many risk factors for imminent subsequent fracture risk have been identified [6] (Table 1).

Clinical risk factors are included in fracture risk assessment tools such as FRAX [54], Garvan [55] and QFracture [56]. FRAX is developed at the University of Sheffield but is until now not endorsed by the WHO [54]. Although FRAX has been internationally validated at the population level, it underestimates the imminent subsequent fracture risk in 65+ patients with a recent fracture [57]. In a recent analysis of the Iceland population by the developers of FRAX, it was reported that in many cases after a recent fracture, the 10 year fracture probability for MOFs as calculated with FRAX underestimated the real imminent fracture risk by more than two-fold. Hazard ratio's ranged between 2.6 and 9.1, depending on the site of fracture, age and sex [58]. The FRAX-BMI scores were below the Canadian threshold for

**Table 1**

Risk factors for imminent subsequent fracture risk (adapted from Roux et al.) [6].

<table>
<thead>
<tr>
<th>Characteristics of sentinel fracture:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Location: higher risk after major fracture than after minor fracture</td>
<td></td>
</tr>
<tr>
<td>Hospitalisation for a clinical VF</td>
<td></td>
</tr>
<tr>
<td>Prevalent VF</td>
<td></td>
</tr>
<tr>
<td>Incident VF</td>
<td></td>
</tr>
<tr>
<td>Prior clinical fracture</td>
<td></td>
</tr>
<tr>
<td>Multiple simultaneous fractures</td>
<td></td>
</tr>
<tr>
<td>Number of prior clinical fractures</td>
<td></td>
</tr>
<tr>
<td>Combination of low BMD with baseline presence, severity and number of VFs</td>
<td></td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
</tr>
<tr>
<td>Increased risk of falls during rehabilitation and follow up after fracture because of walking aids and plastering, and impaired coordination</td>
<td></td>
</tr>
<tr>
<td>Starting high dose of glucocorticoids</td>
<td></td>
</tr>
<tr>
<td>Lower walking speed, poor cognitive function, use of arms for chair stands or poor/very poor tandem stand, Parkinson’s disease, stroke and smoking</td>
<td></td>
</tr>
<tr>
<td>Starting high dose of glucocorticoids</td>
<td></td>
</tr>
</tbody>
</table>
treatment in more than half of the patients at the time of a fragility fracture and in close to a third of
patients with recurrent fragility fracture. One reason could be that FRAX does not specifically include
the risk of falls [57,59]. The predictive potential of Garvan and QFracture algorithms, which include fall
risks, has not been documented after a recent fracture.

These clinical risk factors occur at the background of other risks, such as low body mass index (BMI),
lifestyle (smoking and alcohol) and family history of fractures [60–65].

Subsequent fracture risk is associated with low BMD at the hip, independent of age [66]. Measuring
BMD after a recent fracture, therefore, contributes to fracture risk evaluation and specifies that the
fracture in the patient is indeed ‘osteoporotic’. In frail elderly with a hip fracture, DXA assessment will
often be difficult to perform because of low health status, frailty, low mobility and referral to other
locations such as a revalidation unit or rest home.

Half of the recurrent fractures occurred in patients with osteopenia, and subsequent fracture risk for
low trauma fractures was highest in those who had a prevalent VF [2]. Sub-clinical VFs are frequently
present in patients with a recent NVF [67,68]. Systematic guideline implementation resulted in a
significant increase in imaging of the spine by DXA and diagnosis of VFs in patients visiting the FLS with
an NVF in both genders, at any age, non-VF location and BMD [68]. Therefore, in many patients with a
presumably first NVF, this fracture is, in fact, already a second fracture. In addition, evaluating the
presence, number and severity of a VF by X-Ray or DXA contributes to identify patients at high risk of
subsequent fractures, independent of BMD [69–71].

A history of fall during the last year is associated with a subsequent fracture, independent of a recent
severe low-trauma fracture [72]. Many fall risk factors are related to an imminent fracture risk [73].
Therefore, fall risk evaluation by verifying the history of recent falls and medications and comorbidities
that increase fracture risk contributes to fracture risk evaluation [72–74].

In the above cited overview of FLSs, there is a still high variability in the percentage of patients with
osteoporosis (12–54%), prevalent VFs (20–57%) and fall-related risk factors (60–84%) [49].

Secondary osteoporosis and metabolic bone disorders

Many conditions, diseases and medications have been shown to increase the risk of fractures [75]. Not surprisingly, many patients visiting the FLS report such diseases and medications in their
medical history [76,77]. Approximately 23% reported a history of previously diagnosed diseases
associated with increased fracture risk. However, metabolic bone disorders can be present sub-
clinically and were diagnosed in 27% using a standard laboratory examination [77]. These
sub-clinical newly diagnosed disorders, including low calcium intake and vitamin D deficiency, were
found in both sexes, at all ages, after all fractures and at any level of BMD. Therefore, in addition to
medical history, clinical examination and checking calcium intake and potential risks for vitamin D
deficiency, a limited laboratory investigation is also recommended in all patients with a recent
fracture. In the study of Bours et al. [77], these included serum calcium, albumin, phosphate,
creatinine, TSH, alkaline phosphatase and ESR. Other tests can be performed when indicated, e.g.
protein electrophoresis, testosterone in men less than 70 years old, 25 (OH)D, PTH, tissue trans-
glutaminase and anti-gliadin antibodies, 24-h urine collection (calcium, creatinine, sodium and
phosphate), etc.

In the above-mentioned overview of 33 FLSs, 64% performed laboratory tests [49]. There was a high
variability of newly diagnosed contributors to secondary osteoporosis and other metabolic bone dis-
orders (3–70%) [49].

Initiating and follow up of treatment

Fractures should be managed in a multidisciplinary approach. Immediate treatment of the fracture
led by a trauma or orthopaedic surgeon is needed, and in case of hospital admission, supportive care
should be started and pre-existing comorbidities need attention in collaboration with a dedicated geriatrician [21].

As the FLS is considered the most effective organisation for evaluation and treatment initiation of secondary fracture prevention, an FLS visit is indicated for patients aged 50 years and over with a recent fracture. Treatment is preferably initiated by the supervising clinician at the FLS who is usually a rheumatologist, endocrinologist, internist or geriatrician, depending on the local situation, in collaborations with trauma or orthopaedic surgeons who are providing acute fracture care.

Organisation of FLS care for both inpatients and outpatients, including follow-up, is usually provided by a specialised FLS coordinator, usually an advanced practice provider [18,78].

**Effect of FLS on evaluation, treatment initiation, subsequent fractures and mortality: is FLS cost-effective?**

**Evaluation**

Implementation of a structured FLS resulted in increased patient contacts and education and increased risk evaluation by DXA, by X-ray or DXA for imaging of the spine and by laboratory investigation [10,12,68,79–83]. In contrast, there was no change in exposure to drugs that are known to increase fracture risk [74].

**Therapy initiation**

Implementation of a structured FLS resulted in increased therapy initiation [13,14]. In hip fracture patients, FLS improved non-pharmacologic measures but not the use of osteoporosis medication [84].

Factors associated with post-fracture treatment included osteoporosis medication use before fragility fracture, higher daily calcium intake, diagnosis of osteoporosis, Asian or Pacific Islander race/ethnicity (compared with White/Caucasian), higher income and hormone therapy use (past or present) [12,85,86].

A reduced likelihood of osteoporosis medication use after a fracture included black race, higher Charlson Comorbidity Index scores, presence of dementia, kidney diseases, high BMI, current smoking and history of arthritis [86,87].

**Effect on subsequent fractures**

In a literature search of 22 reports of FLSs, only five FLS studies with heterogeneous study designs were available, which reported on subsequent fracture rate, and three of them reported a lower subsequent fracture rate related to FLS care when comparing fracture rates before and after the introduction of an FLS or when comparing hospitals with and without an FLS [88].

Using an interrupted time series analysis among hip fracture patients, publication of NICE guidance and availability of generic alendronic acid in the UK was associated with increased prescribing and a significant contemporary decline in subsequent major and hip fractures during three years [89]. In contrast, no reduction over two years in second hip fractures was found after introduction of FLS care [20], possibly because of low treatment adherence [20,89]. Brozek et al. found an increased subsequent fracture rate in bisphosphonate users after fracture, which they related not only to longer survival but also to the presence of more comorbidities in bisphosphonate users [90].

In a prospective cohort study during eight years of the Glasgow FLS in 5011 women and men, all patients received adequate calcium and vitamin D, and those at high re-fracture risk were also recommended bisphosphonates (n = 2534) [91]. After adjusting for baseline differences in age, sex and baseline fracture location, those recommended bisphosphonate treatment had a substantially lower risk for subsequent fragility fracture and mortality.
Effect on mortality

Orthogeriatric care and FLS decreased mortality within 30 days and within one year in patients with a hip fracture [20,21,92]. In accordance with the reduced mortality with zoledronate after hip fracture [93], Brozek et al. [90] and Beaupre et al. [94] also reported a lower mortality in hip fracture patients treated with oral bisphosphonates. They also found an increased re-fracture rate, which they related not only to longer survival but also to more comorbidities in BP users [90]. In the above-mentioned long term of the Glasgow FLS, longer survival was also found in those treated for underlying osteoporosis [91].

Cost effectiveness of FLS

There is emerging literature about the cost effectiveness of FLS care [95], using health economic models for the evaluation of preventing fractures. Modelling techniques include simple decision trees, deterministic Markov processes and individual patient simulation models taking into account uncertainty in multiple parameters [95]. Economic evaluation can inform decision makers on the cost-effectiveness of the various interventions and can be the basis for the allocation of scarce healthcare resources [96].

Using Markov models based on epidemiological data and results from RCTs on fracture incidence and prevention, models analysing the effect of treatment on secondary fracture prevention have been statistically shown to be cost-effective after a fragility fracture in preventing second osteoporotic fractures during a mean of six years follow-up [97] or in preventing second hip, wrist and humerus fractures during a mean of eight years follow-up [16].

During a mean follow up of 2.6 years, Leal et al. reported that introduction and/or expansion of Orthogeriatric and nurse-led FLS in patients with a recent hip fracture was more effective and cost-effective than usual care, irrespective of age, sex and Charlson Comorbidity Index score [92]. However, when they incorporated the time to second hip fracture and death and the short- and long-term costs associated with patients with hip fracture, it was not cost-saving, presumably because longer survival could increase costs and re-fractures [92]. Considerable uncertainty remained concerning which of the models of care should be preferred [21,92]. RCTs have been conducted for the comparison of teriparatide with risedronate and romosozumab with alendronate [98,99]. In patients with VFs and a T-score < -1.5, teriparatide was superior to risedronate in preventing vertebral and clinical fractures. Pre-specified sub-group analyses indicated that this superior effect of teriparatide was consistent in a wide range of patients settings, including treatment naïve or previously treated patients, with or without a recent clinical VF or history of NVF and at any age or BMD [100]. In a similar high-risk population, including patients with a history of proximal femur fracture 3–24 months before randomisation, one year romosozumab followed by two years alendronate was superior to three years alendronate in the reduction of the risk of VFs, clinical fractures, NVFs and hip fracture [99]. Because of the higher cost of bone forming agents, direct cost/effectiveness comparisons with anti-resorptive therapy could contribute to select patients in whom bone forming agents can be started based on the level of subsequent fracture risk in daily practice.

Summary

The introduction and implementation of an FLS (and orthogeriatric care after hip fracture) have been shown to increase evaluation and treatment of patients at high risk of having subsequent fracture. There are emerging data that this approach decreases fracture and mortality risk, although longer survival could decrease the effect on fracture risk. Further research will be necessary to study the cost effectiveness of FLS care, based on real-world data and Markov models.
Practice points

In view of the high imminent risk for subsequent fractures after a fracture, the fracture liaison service (FLS) (and orthogeriatric care after hip fracture) is considered the most appropriate organisational approach for secondary fracture prevention following a recent fracture.

Secondary fracture prevention after a recent fracture consists of four pillars:

1/ the logistics of an FLS for organising diagnostic evaluation and treatment decisions;
2/ orthogeriatric care after hip fracture;
3/ identification and invitation of patients with a recent fracture; and
4/ organising adequate follow up.

Research agenda

How to decrease the evaluation and treatment gap for secondary fracture prevention after a recent fracture?
How to improve adherence to therapy?
What is the cost/effectiveness of FLS and orthogeriatric care?

Conflict of interest

The authors have no conflict of interest in the context of this manuscript.

Funding

The authors received no funding for this manuscript.

Acknowledgements

None.

References


